CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Quetzal Therapeutics
Immunome, Inc.
Orca Biosystems, Inc.
Kura Oncology, Inc.
Incyte Corporation
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
Merck Sharp & Dohme LLC
Beijing Biotech
Kura Oncology, Inc.
Hangzhou Sumgen Biotech Co., Ltd.
Celgene
Pfizer
AbbVie
Kumquat Biosciences Inc.
Tcelltech Inc.
Daiichi Sankyo
Vanda Pharmaceuticals
Sellas Life Sciences Group
AvenCell Therapeutics, Inc.
Kura Oncology, Inc.
Caribou Biosciences, Inc.
Swedish Orphan Biovitrum
Tempus AI
Gamida Cell ltd
Gilead Sciences
Faron Pharmaceuticals Ltd
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC
Acrotech Biopharma Inc.
Galapagos NV
Nanjing RegeneCore Biotech Co., Ltd.
AstraZeneca
ImCheck Therapeutics
Prelude Therapeutics
Byondis B.V.
Orca Biosystems, Inc.
Hemanext
Qilu Pharmaceutical Co., Ltd.
Pfizer
Grit Biotechnology
Miltenyi Biomedicine GmbH
Qilu Pharmaceutical Co., Ltd.
CellCentric Ltd.
BeOne Medicines